Autonomic disorders span a wide clinical territory — from common diabetic autonomic neuropathy to rare familial dysautonomia. Diagnostic workup requires systematic evaluation of the autonomic nervous system, identification of patterns of dysfunction (sympathetic vs parasympathetic, central vs peripheral, generalized vs localized), and correlation with specific disease processes. This page covers the diagnostic approach to autonomic dysfunction, specific syndromes with characteristic patterns, and treatment principles for the major autonomic disorders.

Approach to the Patient with Autonomic Symptoms

Common Presenting Symptoms

  • Orthostatic intolerance, syncope, presyncope.
  • Excessive sweating or anhidrosis.
  • Dry mouth, dry eyes.
  • Constipation, gastroparesis.
  • Urinary urgency or retention.
  • Sexual dysfunction.
  • Heat intolerance.
  • Pupillary abnormalities.
  • Fatigue, palpitations, brain fog.

Initial Workup

  • Detailed autonomic symptom history.
  • Medication review (anticholinergics, alpha-blockers, others).
  • Physical examination including supine and standing BP.
  • Cardiovascular evaluation if syncope.
  • Basic laboratory: glucose (diabetes), thyroid function, B12.
  • Autoimmune screening if suspicious: ANA, SSA/SSB, anti-Hu, anti-CV2.

Quantitative Autonomic Testing Battery

Standard testing typically includes (see Function Tests page for details):

  • Deep breathing test.
  • Valsalva maneuver.
  • Tilt table.
  • QSART.
  • Thermoregulatory sweat test (if available).
  • Plasma catecholamines (supine and standing).

Composite Autonomic Severity Score (CASS) quantifies dysfunction.

Specific Autonomic Disorders

Multiple System Atrophy (MSA)

  • Sporadic, progressive, α-synucleinopathy.
  • Three subtypes:
    • MSA-P (parkinsonism predominant).
    • MSA-C (cerebellar predominant).
    • MSA combined.
  • Autonomic features prominent.
  • Clinical features:
    • Orthostatic hypotension.
    • Urinary retention or urgency.
    • Erectile dysfunction.
    • Cold extremities, Raynaud-like.
    • REM sleep behavior disorder.
    • Stridor (laryngeal/diaphragmatic involvement).
  • Differentiated from PD by: severity of autonomic features; less levodopa response; cerebellar features; specific imaging (hot cross bun sign on MRI).
  • Treatment: symptomatic; no disease-modifying therapy currently.

Pure Autonomic Failure (PAF)

  • Profound autonomic failure without other neurologic features.
  • Better prognosis than MSA.
  • Lewy bodies in autonomic ganglia.
  • Diagnostic: orthostatic hypotension + abnormal QSART without parkinsonism or cerebellar features.
  • Treatment: same as MSA-autonomic features.

Parkinson Disease with Autonomic Dysfunction

  • Common feature of PD.
  • Tends to develop in moderate-advanced PD.
  • Symptoms: orthostatic hypotension, constipation, urinary symptoms, sexual dysfunction.
  • Distinguished from MSA by: better levodopa response; lower autonomic burden; lack of cerebellar features.

Diabetic Autonomic Neuropathy

  • Most common cause of autonomic dysfunction.
  • Pathophysiology: distal predominant axonopathy of small unmyelinated fibers.
  • Clinical features:
    • Cardiovagal dysfunction (early): resting tachycardia, decreased HRV.
    • Orthostatic hypotension (late).
    • Gastroparesis, constipation.
    • Erectile dysfunction.
    • Sudomotor: distal anhidrosis with proximal hyperhidrosis.
    • Diabetic gustatory sweating.
  • Workup: comprehensive AFT battery.
  • Treatment: glycemic control, symptomatic management.
  • Predicts cardiovascular mortality.

Familial Dysautonomia (Riley-Day, HSAN-III)

  • Autosomal recessive (IKBKAP/ELP1 mutation).
  • Most common in Ashkenazi Jews.
  • Childhood onset: severe autonomic and sensory symptoms.
  • Hyperhidrosis, GI dysmotility, orthostatic hypotension, hypertensive episodes (“dysautonomic crises”).
  • Treatment: supportive; specific therapies emerging.

Other Hereditary Autonomic Neuropathies

  • HSAN-I (autosomal dominant): adult onset; distal sensory + autonomic loss.
  • HSAN-II (autosomal recessive): congenital; severe.
  • HSAN-IV (congenital insensitivity to pain with anhidrosis): NTRK1 mutation; absent sweating.
  • HSAN-V: NGF mutation; congenital insensitivity to pain.

Acute Pandysautonomia

  • Subacute onset (days to weeks) of severe autonomic dysfunction.
  • Often post-infectious or post-vaccination.
  • Anti-ganglionic AChR antibodies in some.
  • Variable recovery.
  • Treatment: IVIG, plasmapheresis, steroids.

Autoimmune Autonomic Ganglionopathy

  • Autoantibodies against ganglionic nicotinic acetylcholine receptors.
  • Severe autonomic failure.
  • Treatment: IVIG, immunosuppression.

Paraneoplastic Autonomic Neuropathy

  • Anti-Hu, anti-CV2, others.
  • Often with sensory ganglionopathy.
  • Small cell lung cancer most common.
  • Treatment: cancer treatment + immunotherapy.

Sjögren Syndrome Autonomic Neuropathy

  • Small-fiber neuropathy with autonomic involvement.
  • Sometimes severe pandysautonomia.
  • Anti-Ro/SSA positive.
  • Treatment: immunotherapy, sicca symptom management.

Amyloid Autonomic Neuropathy

  • ATTR (transthyretin) hereditary amyloidosis: progressive autonomic failure.
  • AL (light chain) amyloidosis.
  • Treatment: emerging — tafamidis, patisiran, vutrisiran for ATTR.

HIV-Associated Autonomic Neuropathy

  • Can occur with HIV or as side effect of antiretrovirals.
  • Variable severity.

Botulism

  • Acute autonomic failure (anticholinergic effects).
  • Dry mouth, urinary retention, gastroparesis, mydriasis.
  • Combined with descending paralysis.
  • Treatment: antitoxin.

Tetanus

  • Severe sympathetic overactivity.
  • Hypertension, tachycardia, sweating.
  • Treatment: antitoxin + magnesium for autonomic features.

Postural Orthostatic Tachycardia Syndrome (POTS)

  • Sustained HR increase >30 bpm (or HR >120) within 10 min of standing without orthostatic hypotension.
  • Heterogeneous etiologies:
    • Neuropathic (small-fiber autonomic dysfunction).
    • Hyperadrenergic (excessive sympathetic activation).
    • Hypovolemic.
    • Combinations.
  • Female predominance (15:1).
  • Young adult onset typically.
  • Often follows viral illness, surgery, or trauma.
  • Treatment:
    • Salt loading (8–10 g daily).
    • Fluids (3–4 L daily).
    • Exercise reconditioning (gradual recumbent then upright).
    • Beta-blockers (especially propranolol, atenolol).
    • Ivabradine.
    • Fludrocortisone in some.

Vasovagal Syncope (Neurally Mediated)

  • Sudden BP and HR drop in response to specific triggers.
  • Triggers: prolonged standing, blood draw, pain, emotional stress.
  • Three types on tilt table:
    • Cardioinhibitory (HR drop predominant).
    • Vasodepressor (BP drop predominant).
    • Mixed.
  • Treatment: trigger avoidance, counter-pressure maneuvers, beta-blockers (variable benefit), pacing in cardioinhibitory.

Treatment Principles

Orthostatic Hypotension Management

Non-pharmacologic

  • Increase salt (8–10 g/day) and fluid (2–3 L/day).
  • Head-of-bed elevation (10–20°).
  • Compression stockings.
  • Abdominal binder.
  • Rising slowly from supine.
  • Avoid hot environments.
  • Frequent small meals.

Pharmacologic

  • Fludrocortisone 0.1–0.3 mg daily (volume expansion).
  • Midodrine 2.5–10 mg TID (α1 agonist; avoid late in day).
  • Droxidopa (Northera): NE precursor.
  • Pyridostigmine 30–60 mg TID.
  • Caffeine, ergotamines (less commonly).

Gastroparesis

  • Frequent small meals.
  • Metoclopramide (avoid in PD).
  • Erythromycin.
  • Domperidone (where available).
  • Prokinetic motility agents.

Urinary Dysfunction

  • OAB: mirabegron preferred over anticholinergics (less cognitive burden).
  • Retention: bethanechol, catheterization.
  • α1 blockers for outlet obstruction.

Erectile Dysfunction

  • PDE5 inhibitors.
  • Address contributing factors.

Constipation

  • Polyethylene glycol.
  • Lubiprostone, prucalopride.
  • Avoid metoclopramide in PD.

Hyperhidrosis

  • Topical agents.
  • Botulinum toxin for focal.
  • Anticholinergics (cognitive trade-off).

Specific Considerations

Supine Hypertension with Orthostatic Hypotension

  • Common in autonomic failure (lying down → severe HTN; standing → OH).
  • Head-of-bed elevation helps.
  • Avoid antihypertensives that worsen OH.
  • Sometimes use nighttime nitrates or short-acting agents.

Postprandial Hypotension

  • BP drop after meals.
  • Common in autonomic failure.
  • Small frequent meals, low carbohydrate.
  • Caffeine.
  • Acarbose to slow carbohydrate absorption.

Heat Intolerance

  • Common in autonomic dysfunction.
  • Cool environments, hydration.
  • Monitor for hyperthermia in patients with anhidrosis.

🔍 Did You Know?

The recognition that diabetic autonomic neuropathy is an independent predictor of cardiovascular mortality has transformed how it’s evaluated and managed. In patients with diabetes, the presence of cardiac autonomic neuropathy (measured by reduced heart rate variability or abnormal Valsalva ratio) doubles or triples mortality risk over 5–10 years, with most excess deaths due to sudden cardiac events, silent myocardial infarction, and arrhythmias. The clinical implication is profound: autonomic testing in diabetes is not just diagnostic but prognostic, and abnormal findings should trigger more intensive cardiovascular risk management — optimization of BP, lipids, and antiplatelet therapy; consideration of preventive cardiology consultation; sometimes implantable cardiac monitoring. The same principle applies to other autonomic disorders: severe autonomic failure portends increased mortality from cardiovascular causes (fatal arrhythmia, silent MI) and from secondary causes (falls from syncope, aspiration from gastroparesis). For practicing neurologists, the take-home is that autonomic dysfunction quantification provides risk stratification, not just symptom characterization, and patients with significant autonomic findings warrant comprehensive cardiovascular evaluation. The lesson generalizes: autonomic neurophysiology bridges neurology and cardiology, and treating autonomic dysfunction is part of integrated cardiovascular care, particularly in diabetes, heart failure, and post-arrest patients. The cardiovascular and neurology communities are increasingly collaborating on autonomic testing protocols and treatment guidelines.

Pitfalls and Pearls

  • Autonomic symptom history: orthostatic, GI, urinary, sexual, sweating, palpitations.
  • Always check supine + standing BP: simple bedside autonomic test.
  • MSA: parkinsonism + autonomic + cerebellar + RBD; stridor warning.
  • Pure autonomic failure: severe autonomic without other features; better prognosis.
  • Diabetic autonomic neuropathy: most common; predicts cardiovascular mortality.
  • Familial dysautonomia: Ashkenazi Jewish; childhood onset.
  • Autoimmune autonomic ganglionopathy: ganglionic AChR antibodies; IVIG treatment.
  • Paraneoplastic autonomic neuropathy: anti-Hu, SCLC; immunotherapy.
  • Sjögren autonomic neuropathy: anti-Ro/SSA; sicca; immunotherapy.
  • ATTR amyloid autonomic: hereditary; tafamidis, patisiran emerging treatments.
  • POTS: HR rise >30 within 10 min standing; young women; salt + fluid + exercise + beta-blocker.
  • Vasovagal syncope: trigger avoidance, counter-pressure, beta-blockers.
  • Supine HTN + OH: head-of-bed elevation; avoid OH-worsening antihypertensives.
  • OH treatment: non-pharm first; fludrocortisone, midodrine, droxidopa.
  • Mirabegron preferred over anticholinergics for OAB.
  • Avoid metoclopramide in PD: worsens motor symptoms.
  • Autonomic findings = cardiovascular risk: integrate into CV risk management.

References

  1. Low PA. Clinical Autonomic Disorders. 3rd ed. Lippincott Williams & Wilkins; 2008.
  2. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264-274.
  3. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.
  4. Vernino S, Lennon VA. Autoimmune autonomic ganglionopathy. Continuum (Minneap Minn). 2014;20(5):1316-1324.
  5. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21.
  6. Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the diagnosis and treatment of postural tachycardia syndrome. Heart Rhythm. 2015;12(6):e41-63.